Brief: ImmixBio IMX-110 Produced 50% Positive Response Rate In First-Line-Therapy-Resistant Cancer, Surpassing The Standard Of Care In Mice Study

Immix Biopharma

12/01/2022 13:08

Jan 12 (Reuters) - Immix Biopharma Inc  IMMX.O :
    * IMMIXBIO IMX-110 PRODUCED 50% POSITIVE RESPONSE RATE IN
FIRST-LINE-THERAPY-RESISTANT CANCER, SURPASSING THE STANDARD OF
CARE IN MICE STUDY
    * IMMIX BIOPHARMA INC - IMX-110 RESPONSE RATE SURPASSED
STANDARD
OF CARE DOXORUBICIN'S RESPONSE RATE OF 0% AFTER 1 CYCLE OF
TREATMENT IN SAME STUDY

Source text for Eikon:  ID:nGNX1qTKXy 
Further company coverage:  IMMX.O 

 ((Reuters.Briefs@thomsonreuters.com;))